Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 225

Results For "Pharma"

5071 News Found

Glenmark launches world’s first nebulized triple therapy for COPD
News | November 27, 2025

Glenmark launches world’s first nebulized triple therapy for COPD

Clinical studies conducted in India demonstrated that this nebulized triple therapy rapidly improves lung function and offers better control of breathlessness


Novo Nordisk fast-tracks higher-dose obesity drug to FDA
Clinical Trials | November 27, 2025

Novo Nordisk fast-tracks higher-dose obesity drug to FDA

The drug, intended for chronic weight management alongside diet and exercise, is now under the FDA’s new CNPV expedited review pathway


Kelun-Biotech’s Sac-TMT shows breakthrough results in first-line lung cancer trial
Clinical Trials | November 27, 2025

Kelun-Biotech’s Sac-TMT shows breakthrough results in first-line lung cancer trial

Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors


Otsuka files FDA application for first-in-class ADHD drug
Clinical Trials | November 27, 2025

Otsuka files FDA application for first-in-class ADHD drug

Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor


Novo Nordisk’s new diabetes combo drug delivers big wins in mid-stage trial
Clinical Trials | November 26, 2025

Novo Nordisk’s new diabetes combo drug delivers big wins in mid-stage trial

The trial tested six injectable doses and three oral doses over as long as 36 weeks


Novartis scores FDA nod for game-changing SMA treatment
Biotech | November 26, 2025

Novartis scores FDA nod for game-changing SMA treatment

Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA


Telangana fires up biologics innovation, debuts India's first single-use bioprocess scale-up hub
R&D | November 25, 2025

Telangana fires up biologics innovation, debuts India's first single-use bioprocess scale-up hub

The State’s PPP model has already mobilised Rs. 150 crore in core infrastructure, while Thermo Fisher has invested Rs. 90 crore in the Bioprocess Design Centre and its co-located Customer Experience Centre